Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen

Lymphoma

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group

Eur J Cancer

Ostrowska B, Domanska-Czyz K, Giza A, Taszner M, Tomaszewska A, Targonski L, Dabrowska-Iwanicka A, Poplawska L, Konecki R, Kotarska M, Szymanski M, Borawska A, Swierkowska M, Druzd-Sitek A, Paszkiewicz-Kozik E, Mroz-Zycinska E, Zimowska-Curyło D, Owczarek-Kaczmarek J, Drozd-Sokolowska J, Tajer J, Osiadacz W, Rymkiewicz G, Michalski W, Basak G, Krzanowski J, Sacha T, Zaucha JM, Walewski J, Romejko-Jarosinska J

doi: 10.1016/j.ejca.2026.116789

Further Publications

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Ann Oncol

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff MM, Joshua AM, Ochsenreither S, Gastaud L, Curti BD, Demidov LV, Milhem MM, Chmielowski B, Kendra KL, Ascierto PA, Bernicker EH, Carvajal RD, Collins L, Lockwood S, Patel JM, Hamid OA, Baurain JF, Nathan PD

doi: 10.1016/j.annonc.2026.05.695

Skin Cancer

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Eur J Cancer

Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, Olofsson Bagge R

doi: 10.1016/j.ejca.2025.116201

ESMO 2026

Genitourinary Cancer

EV-103: Enfortumab vedotin plus pembrolizumab shows sustained survival and durable responses after five years of follow-up in advanced urothelial carcinoma

Lymphoma

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL

Blood

Abramson JS, Siddiqi T, Gordon LI, Lunning MA, Wang M, Arnason JE, Kamdar M, Maloney DG, Shadman M, Andreadis CB, Sehgal A, Solomon SR, Ghosh N, Hidalgo-López JE, Wang J, Ding X, Ogasawara K, Singh A, Palomba ML

doi: 10.1182/blood.2025032270

Further Publications

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

J Clin Oncol

Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ

doi: 10.1200/JCO-25-00507

Lymphoma

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Haematologica

Rocha V, Mooyaart JE, Ram R, Clesham K, Daskalakis M, Huynh A, Potter V, Chaganti S, Gabellier L, Tholouli E, Collin M, Nicholson E, Protheroe R, Passweg J, Ayuk F, Schneidawind D, Kwon M, Corral LL, Zeiser R, Scheid C, Yakoub-Agha I, Dreger P, Stolzel F, Hoogenboom J, Coelho MHM, Tomas AA, Malard F, Kuball J, Sureda A, Barzabachi A, Ruggeri A

doi: 10.3324/haematol.2026.300508

Breast Cancer

Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry

Breast

Gampenrieder SP, Castagnaviz V, Bartsch R, Sliwa T, Pichler A, Pusch R, Dormann C, Suppan C, Heibl S, Scagnetti L, Sandholzer M, Winder T, Zabernigg AF, Schmitt C, Egle D, Hager C, Pichler P, Roitner F, Andel J, Strasser-Weippl K, Hubalek M, Knauer M, Singer CF, Greil R, Rinnerthaler G

doi: 10.1016/j.breast.2026.104891

COVID-19

Impact of the COVID-19 pandemic and its measures on one-year and three-year cancer survival using Swiss cantonal cancer registry data

Cancer Causes Control

Suter F, Wanner M, Wicki A, Korol D, Rohrmann S

doi: 10.1007/s10552-026-02175-8

Related content

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

EV-103: Enfortumab vedotin plus pembrolizumab shows sustained survival and durable responses after five years of follow-up in advanced urothelial carcinoma

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry

Impact of the COVID-19 pandemic and its measures on one-year and three-year cancer survival using Swiss cantonal cancer registry data